未登录

M

Michael Hennig

Helmholtz Association

H指数:33

被引数:4,102

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-World Experience on the Use of Mepolizumab from the Severe Asthma Registry of the German Asthma Net (MepoGAN-Study)

JOURNAL OF ASTHMA AND ALLERGY

IF3

2023-05-016

OAAI

Is IQWiG's 15% Threshold Universally Applicable in Assessing the Clinical Relevance of Patient-Reported Outcomes Changes? An ISPOR Special Interest Group Report

VALUE IN HEALTH

IF6

2022-09-014

OAAI

Release of 14C-labelled carbon nanotubes from polycarbonate composites

ENVIRONMENTAL POLLUTION

IF7.3

2016-08-0126

PREAI

The metabolite 3,4,3′,4′-tetrachloroazobenzene (TCAB) exerts a higher ecotoxicity than the parent compounds 3,4-dichloroaniline (3,4-DCA) and propanil

SCIENCE OF THE TOTAL ENVIRONMENT

IF8

2016-05-0116

PREAI

Meeting the Needs for Released Nanomaterials Required for Further Testing-The SUN Approach

ENVIRONMENTAL SCIENCE & TECHNOLOGY

IF11.3

2016-03-0458

OA

A multicentre, randomized, single-blind, parallel-group study comparing the efficacy and tolerability of benzoyl peroxide 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of mild-to-moderate acne vulgaris

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

IF8

2016-02-2422

PREAI

The Role of Relative Lymphocyte Count as a Biomarker for the Effect of Catumaxomab on Survival in Malignant Ascites Patients: Results from a Phase II/III Study

CLINICAL CANCER RESEARCH

IF10.2

2014-06-1218

PREAI

How flood events affect rainbow trout: Evidence of a biomarker cascade in rainbow trout after exposure to PAH contaminated sediment suspensions

AQUATIC TOXICOLOGY

IF4.3

2013-03-0140

PREAI

Immunomonitoring Results of a Phase II/III Study of Malignant Ascites Patients Treated with the Trifunctional Antibody Catumaxomab (Anti-EpCAM x Anti-CD3)

CANCER RESEARCH

IF16.6

2012-01-0297

OAAI

Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites

INTERNATIONAL JOURNAL OF CANCER

IF4.7

2011-09-2774

OAAI

Baseline Values but Not Treatment-Induced Changes in Carotid Intima-Media Thickness Predict Incident Cardiovascular Events in Treated Hypertensive Patients Findings in the European Lacidipine Study on Atherosclerosis (ELSA)

IF38.6

2009-09-22108

OAAI

Assessment of long-term antihypertensive treatment by clinic and ambulatory blood pressure: data from the European Lacidipine Study on Atherosclerosis

通过临床和动态血压评估长期抗高血压治疗: 来自欧洲拉西地平动脉粥样硬化研究的数据

JOURNAL OF HYPERTENSION

IF4.1

2007-05-0155

PREAI

Effect of a milk drink supplemented with whey peptides on blood pressure in patients with mild hypertension

EUROPEAN JOURNAL OF NUTRITION

IF4.3

2006-12-1597

PREAI

Prophylaxis of contrast material-induced nephropathy in patients in intensive care: Acetylcysteine, theophylline, or both? A Randomized study

IF15.2

2006-06-0166

PRE

Randomized clinical trial of vertical or transverse laparotomy for abdominal aortic aneurysm repair

BRITISH JOURNAL OF SURGERY

IF8.7

2005-09-2051

OAAI

Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer

BRITISH JOURNAL OF CANCER

IF6.8

2005-07-1286

OAAI

Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial

BRITISH JOURNAL OF CANCER

IF6.8

2005-06-0755

OAAI

Carotid wall composition in hypertensive patients after 4-year treatment with lacidipine or atenolol: an echoreflectivity study

JOURNAL OF HYPERTENSION

IF4.1

2005-06-0117

PREAI

Quality control of B-mode ultrasonic measurement of carotid artery intima-media thickness: the European Lacidipine Study on Atherosclerosis

JOURNAL OF HYPERTENSION

IF4.1

2005-05-0125

PREAI

Cardiac structural and functional changes during long-term anti hypertensive treatment with lacidipine and atenolol in the European Lacidipine Study on Atherosclerosis (ELSA)

JOURNAL OF HYPERTENSION

IF4.1

2005-05-0124

PREAI